After encouraging word from Europe, PTC Therapeutics Inc.’s “first strategy is to continue to try and push forward [in FDA discussions] with the data that we’ve got,” Chief Financial Officer Shane Kovacs told BioWorld Today. “Why should the kids wait another three years?”